SV2007002007A - Compuestos de quinolina sustituidos ref. pc 25932a - Google Patents

Compuestos de quinolina sustituidos ref. pc 25932a

Info

Publication number
SV2007002007A
SV2007002007A SV2005002007A SV2005002007A SV2007002007A SV 2007002007 A SV2007002007 A SV 2007002007A SV 2005002007 A SV2005002007 A SV 2005002007A SV 2005002007 A SV2005002007 A SV 2005002007A SV 2007002007 A SV2007002007 A SV 2007002007A
Authority
SV
El Salvador
Prior art keywords
substituted quinoline
quinoline compounds
compounds ref
compounds
ref
Prior art date
Application number
SV2005002007A
Other languages
English (en)
Inventor
Peter Bertinato
Michel Andre Couturier
Ernest Seiichi Hamanaka
Marcus Douglas Ewing
Ralph Pelton Robinson Jr
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2007002007A publication Critical patent/SV2007002007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

ESTA INVENCIÓN SE REFIERE A INHIBIDORES DE LA SECRECIÓN DE MTP/APO-B DE FORMULA (I) VER FORMULA DONDE R1-R7, X1, M Y N SON COMO SE HAN DEFINIDO EN LA MEMORIA DESCRIPTIVA, ASÍ COMO COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS, A PROCEDIMIENTOS DE USO DE LOS COMPUESTO Y COMPOSICIONES. LOS COMPUESTOS DE LA INVENCIÓN SON ÚTILES EN EL TRATAMIENTO DE LA OBESIDAD Y ENFERMEDADES, AFECCIONES O TRASTORNOS ASOCIADOS
SV2005002007A 2004-02-04 2005-02-04 Compuestos de quinolina sustituidos ref. pc 25932a SV2007002007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
SV2007002007A true SV2007002007A (es) 2007-03-20

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002007A SV2007002007A (es) 2004-02-04 2005-02-04 Compuestos de quinolina sustituidos ref. pc 25932a

Country Status (25)

Country Link
US (3) US7468378B2 (es)
EP (1) EP1716137A1 (es)
JP (1) JP2007520543A (es)
KR (1) KR100799802B1 (es)
AP (1) AP2006003685A0 (es)
AR (1) AR047529A1 (es)
AU (1) AU2005214159A1 (es)
BR (1) BRPI0507462A (es)
CA (1) CA2555133A1 (es)
CO (1) CO5700721A2 (es)
CR (1) CR8544A (es)
EA (1) EA010369B1 (es)
EC (1) ECSP066717A (es)
GE (1) GEP20084360B (es)
IL (2) IL176715A0 (es)
MA (1) MA28347A1 (es)
NL (1) NL1028192C2 (es)
NO (1) NO20063928L (es)
OA (1) OA13365A (es)
PA (1) PA8623001A1 (es)
PE (1) PE20050773A1 (es)
SV (1) SV2007002007A (es)
TW (2) TWI306454B (es)
UY (1) UY28734A1 (es)
WO (1) WO2005080373A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
EA010369B1 (ru) * 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005100325A1 (en) * 2004-04-14 2005-10-27 Astrazeneca Ab Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2605510C (en) 2005-04-19 2013-12-24 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
ATE520651T1 (de) * 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
WO2008059335A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008097471A1 (en) * 2007-02-02 2008-08-14 Shivvers Steve D High efficiency drier with multi stage heating and drying zones
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
EP2209371B1 (en) 2007-10-19 2017-01-04 SARcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
US8710043B2 (en) 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
ES2552989T3 (es) * 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2015121877A2 (en) * 2014-02-17 2015-08-20 Hetero Research Foundation Polymorphs of lomitapide and its salts
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2016055934A1 (en) * 2014-10-09 2016-04-14 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
RS62670B1 (sr) 2016-09-30 2021-12-31 Vertex Pharma Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
JP6906105B2 (ja) * 2017-06-16 2021-07-21 成都先導薬物開発股▲ふん▼有限公司Ｈｉｔｇｅｎ Ｌｔｄ． Ｒｏｃｋを阻害する化合物及びその使用
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
DK104382A (da) 1981-03-11 1982-09-12 Wellcome Found Fremgangsmaade til fremstilling af substituerede biphenylforbindelser
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
BR9507788A (pt) 1994-05-27 1997-09-23 Smithkline Beecham Spa Composto ou solvato ou sal do mesmo processo para a preparação do composto composição farmacêutica antagonista do receptor de NK3 uso do composto uso do antagonista do receptor de NG3 e processo para o tratamento e/ou profilaxia de distúrbios pulmonares e distúrbios convulsivos
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
ATE233734T1 (de) 1995-06-07 2003-03-15 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
CZ296163B6 (cs) 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
AU3513497A (en) 1996-07-01 1998-01-21 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
CA2309882A1 (en) 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
IL139449A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
US20020032238A1 (en) 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
NZ525591A (en) 2000-10-05 2004-04-30 Fujisawa Pharmaceutical Co Benzamide compounds as Apo B secretion inhibitors
CN1880304B (zh) 2001-06-28 2010-11-24 辉瑞产品公司 三酰胺取代的吲哚、苯并呋喃及苯并噻吩
CZ2004634A3 (cs) 2001-10-25 2004-10-13 Takedaáchemicaláindustriesźáltd Chinolinová sloučeninaŹ způsob výroby a použití a farmaceutický přípravek
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US20030162788A1 (en) 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
ZA200502496B (en) 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
EP1581499A1 (en) * 2002-12-20 2005-10-05 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
WO2004056777A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
EA010369B1 (ru) * 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения

Also Published As

Publication number Publication date
US20050234099A1 (en) 2005-10-20
US20070093525A1 (en) 2007-04-26
CA2555133A1 (en) 2005-09-01
EA010369B1 (ru) 2008-08-29
US7368573B2 (en) 2008-05-06
AP2006003685A0 (en) 2006-08-31
WO2005080373A1 (en) 2005-09-01
PE20050773A1 (es) 2005-10-26
AU2005214159A1 (en) 2005-09-01
JP2007520543A (ja) 2007-07-26
TWI306454B (en) 2009-02-21
US7468378B2 (en) 2008-12-23
CO5700721A2 (es) 2006-11-30
AR047529A1 (es) 2006-01-25
BRPI0507462A (pt) 2007-07-10
NO20063928L (no) 2006-10-31
CR8544A (es) 2006-11-30
NL1028192A1 (nl) 2005-08-08
ECSP066717A (es) 2006-10-31
GEP20084360B (en) 2008-04-29
IL208963A0 (en) 2011-07-31
EP1716137A1 (en) 2006-11-02
US7393958B2 (en) 2008-07-01
US20060223851A1 (en) 2006-10-05
PA8623001A1 (es) 2006-03-24
OA13365A (en) 2007-04-13
IL176715A0 (en) 2006-10-31
KR100799802B1 (ko) 2008-01-31
TW200533354A (en) 2005-10-16
MA28347A1 (fr) 2006-12-01
TW200906800A (en) 2009-02-16
KR20060127123A (ko) 2006-12-11
NL1028192C2 (nl) 2006-05-30
EA200601239A1 (ru) 2007-02-27
UY28734A1 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
SV2007002007A (es) Compuestos de quinolina sustituidos ref. pc 25932a
ECSP088869A (es) Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
SV2010003497A (es) Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY28945A1 (es) Derivados de pirrolopiridina
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
HN2008001666A (es) Derivados acidos de cicloalquilamino
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
GT200700075A (es) Derivados de eter diarilico y usos de los mismos
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene
GT200500016A (es) Compuestos de quinolina sustituidos
DOP2010000257A (es) Compuesto ( r) -n*6*-etil-6,7-dihidro-5h-indeno(5,6-d)tiazol-2,6-diamina y su uso como antipsicotico
DOP2005000015A (es) Compuestos de quinolina sustituidos
BRPI0513386A (pt) inibidores de reabsorção de norepinefrina de quinoxalinona para o tratamento de distúrbios do sistema nervoso central
SV2005002056A (es) Derivados de formamida para el tratamiento de enfermedades ref. pc32168a

Legal Events

Date Code Title Description
FA Abandonment
FD Lapse